about
Parasitic diarrheal disease: drug development and targetsClinically Available Medicines Demonstrating Anti-Toxoplasma ActivityMalaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a reviewThe Potential Use of Natural and Structural Analogues of Antimicrobial Peptides in the Fight against Neglected Tropical DiseasesRepurposing drugs for the treatment and control of helminth infectionsActivity Profile of an FDA-Approved Compound Library against Schistosoma mansoniTargeting Lysine Deacetylases (KDACs) in ParasitesPathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB)Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprinaEvolution of Chagas' disease in Brazil. Epidemiological perspective and challenges for the future: a critical review.Translational Rodent Models for Research on Parasitic Protozoa-A Review of Confounders and PossibilitiesDeep Insight into the Phosphatomes of Parasitic Protozoa and a Web Resource ProtozPhosDB.An antioxidant response is involved in resistance of Giardia duodenalis to albendazole.Leishmanicidal Effect of Synthetic trans-Resveratrol Analogs.Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasitesPharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health TransitionIn vitro antileishmanial and antimalarial activity of selected plants of NepalFluorinated Sterols Are Suicide Inhibitors of Ergosterol Biosynthesis and Growth in Trypanosoma brucei.Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations.Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.Repurposing of antiparasitic drugs: the hydroxy-naphthoquinone buparvaquone inhibits vertical transmission in the pregnant neosporosis mouse modelAntileishmanial and Cytotoxic Activity of Some Highly Oxidized Abietane Diterpenoids from the Bald Cypress, Taxodium distichumIn silico methods for drug repurposing and pharmacologyClofazimine Inhibits the Growth of Babesia and Theileria Parasites In Vitro and In Vivo.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasisCryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase.Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration.Lectins from Synadenium carinatum (ScLL) and Artocarpus heterophyllus (ArtinM) Are Able to Induce Beneficial Immunomodulatory Effects in a Murine Model for Treatment of Toxoplasma gondii Infection.Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.Clinical implications of recent findings in schistosome proteomics.Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.Resisting resistance: is there a solution for malaria?Drug target identification in protozoan parasites.Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection.Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous LeishmaniasisAntisense antimicrobial therapeuticsTrypanocidal action of Lippia alba and Lippia origanoides essential oils against Trypanosoma evansi in vitro and in vivo used mice as experimental model.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Targeting proteasomes in infectious organisms to combat disease.Polymeric therapeutic delivery systems for the treatment of infectious diseases.
P2860
Q26776140-8A30E327-47A9-455F-9D57-CC3BE7E61B00Q26782581-277DD2EC-EFEA-4EAF-B16B-02DA3FD5AE1CQ26786020-ED4AFFC4-22B7-42A0-9245-4E8B3E812784Q26797488-44B7FE8A-78EF-4C7E-BCB6-4337E27CA100Q26823355-C61DC2C5-8280-4873-B46F-602A448C436CQ28546955-8D964C11-5E62-45F1-8ECB-DE13A4198D30Q28548415-8116BA7D-C835-4059-B583-C32BC8C9C858Q28550034-03F02A13-AB64-4517-9B2D-B04F606235BEQ28818731-127FAABB-D36A-47A0-BB9F-3911C5912DA6Q30244332-6AD27FA0-B971-47F9-AACB-97DC9403469AQ33770491-027C38D4-95BC-403A-A0B9-6E88554025D2Q34546904-6C803329-9684-4B68-80A1-18F403190836Q35352651-C6A8167F-0192-41A2-B64D-328B8882B670Q35827365-0C962F4F-6D13-4706-B2DF-3D1CCD11B55FQ35864886-9DD62BF9-B3CA-4C4B-928E-DAC15964CB32Q36105822-4EBED41E-C733-47E3-B0B9-3B1FE01AD16DQ36167211-AD5CEF01-F41F-429C-AE32-7ABC41FF59EDQ36219533-71B2D424-3823-4689-9415-B9D002705A8EQ36296803-7D271F38-FC3A-4F72-8E86-8DD3A0FEEFDEQ36298245-4443B7D9-9380-40E0-82FB-15FE24CF81A6Q36588120-07504FD6-3127-4515-A145-50330A96BE41Q36796525-67940CC1-B45D-4192-830C-DA9C589F944DQ36837816-3D93F193-B9D8-4828-B221-CD84E9F63C4CQ36888131-CE85CAA3-6354-40A5-B409-E14ADC28CCC1Q36932080-6056C389-A17A-4C1D-933A-0C38496CD8C6Q37287878-401AE716-E135-4C0A-AF1D-6881F2BE8FA0Q37334397-0DF1019F-A4C6-40FB-B951-823A2ACE700FQ37438089-0DDE04AE-8D4A-4127-AAE3-66CEBF56394BQ37591018-095E1F17-3A8E-46B7-9E05-65B273254E6EQ38630566-C0C83E80-C1BB-47E3-8235-2508FC4EDA30Q38668340-52F63C44-AB71-46EC-865F-9D015FE247E2Q38755043-39408A7B-6D0D-482D-BE00-1AF84563D4A2Q38847814-06768537-A1A3-4A40-AB6A-DF453594E0B2Q38864252-D2C77AB4-38F2-487C-BC77-469BE3F576C3Q38875177-080DF1D6-5D19-4ADB-940D-CFED37C8D4ECQ38885150-29035134-A479-49A1-A037-6CFB1E77FDCAQ38889915-0EAE1404-BFC6-4499-8E89-125FEB9DA901Q38939544-27FE6E00-704F-42AB-A76D-63D20C92D444Q39103077-CCC48084-F45E-483D-BA6E-33C842D528F8Q39386505-CE4C626A-4444-4A7B-83D6-6D14A75FB8E6
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Drug repurposing and human parasitic protozoan diseases
@ast
Drug repurposing and human parasitic protozoan diseases
@en
Drug repurposing and human parasitic protozoan diseases
@nl
type
label
Drug repurposing and human parasitic protozoan diseases
@ast
Drug repurposing and human parasitic protozoan diseases
@en
Drug repurposing and human parasitic protozoan diseases
@nl
prefLabel
Drug repurposing and human parasitic protozoan diseases
@ast
Drug repurposing and human parasitic protozoan diseases
@en
Drug repurposing and human parasitic protozoan diseases
@nl
P2860
P50
P3181
P1476
Drug repurposing and human parasitic protozoan diseases
@en
P2093
Katherine T. Andrews
Tina S. Skinner-Adams
P2860
P304
P3181
P356
10.1016/J.IJPDDR.2014.02.002
P407
P577
2014-03-24T00:00:00Z